NovaTears®+Omega-3, an innovative dry eye treatment in-licensed and distributed in Australia and New Zealand by AFT Pharmaceuticals, is a significantly effective treatment for evaporative Dry Eye Disease (DED), a new clinical study1 has found.
Please see the attached announcement for more information.
The S&P/NZX 50 Index rose 97.07 points, or 0.8%, to 12,447.68.
Fletcher Building subsidiary Iplex Australia to cover 80% of repair costs.
The bus operator's net loss widened from $8m to $17m in the year to March 31.
To join your company account for BusinessDesk and enjoy full access, enter your email and we’ll send you details